Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer

British Journal of Cancer

Volumn 91, Issue 10, 2004, Pages 1758-1762

  Feliu, J ^a   Vicent, J M ^b   Garcia Giron C ^c   Constela, M ^d   Fonseca, E ^e   Aparicio, J ^f   Lomas, M ^g   Anton Aparicio L ^h   Dorta, F J ⁱ   Gonzalez Baron M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d Medical Oncology Service   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL INFANTA CRISTINA   (Spain)

^h HOSPITAL JUAN CANALEJO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Colorectal cancer chemotherapy; Leucovorin; Oxaliplatin; UFT

Indexed keywords

AMINOTRANSFERASE; FOLINIC ACID; OXALIPLATIN; UFT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; EVALUATION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LARYNGOPHARYNGEAL REFLUX; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ORGANOPLATINUM COMPOUNDS; STOMATITIS; SURVIVAL ANALYSIS; TEGAFUR; URACIL; VOMITING;

EID: 10844241474     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602217     Document Type: Article

References (34)

1. Advanced Colorectal Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903
2. Bertheault-Cvitkovik F, Jami A, Ithzaki M, Brummer PD, Brienza S, Adam R, Kustlinger F, Bismuth H, Misset JL, Levi F (1996) Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14: 2950-2958
3. Borner MM, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358
4. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oca A, Skovsgaard T, Munier S, Martin C (2002) Randomized coparative study of tegafur/uracil and oral leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627
5. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
6. Douillard JY, Bennoua J, Artru P, Perrier H, Paillot B, Hussein F, Priou F, Imadalou K, Delord JP, Bugat R (2004) UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (pts) with non respectable metastatic colorectal cancer (MCRC): results of two multicentric phase II trials. Proc Am Soc Clin Oncol 23: 256 (abstr. 3545)
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
8. Douillard J-Y, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616
9. Eng C, Kindler HL, Schilsky RL (2001) Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer 1: 95-103
10. Feliu J, González Barón M, Espinosa E, García Girón C, de la Gándara I, Espinosa J, Colmenarejo A, Jalón JI, Fernández Y, de Castro J (1997) Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 79: 1884-1889
11. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
12. Fujii S, Kitano S, Irenaka K, Shirasak T (1979) Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 6: 377-384
13. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitovich F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levy F (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147
14. Goldberg R, Morton R, Sargent D, Fuschs C, Ramanthan RK, Williamson SK, Findley BP (2003) N9741: oxaliplatin or CPT-11+5-fluorouracil/leucovorin or oxa+CPT 11 in advanced colorectal cancer. Updated efficacy and quality of life data from an intergroup study. Proc Am Soc Clin Oncol 22: 252 (abstr. 1009)
15. González Barón M, Feliu J, de la Gándara I, Espinosa E, Colmenarejo A, Martínez B, Blanco E, García-Girón C, Juárez F, Garrido P, Ordóñez A, Zamora P (1995) Efficacy of oral tegafur modulation by uracil (UFT) and leucovorin in advanced colorectal cancer: a phase II study. Eur J Cancer 31:2215-2219
16. González-Barón M, Feliu J, Ordóñez A, Colmenarejo A, Espinosa E, Zamora P, de la Gándara I, Jalón JI. (1993) Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res 13: 759-762
17. Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2-tetrahydrofuryl)- 5-fluorouracil. Clin Cancer Res 4: 2085-2088
18. Kim K, Nam E, Lee NS, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK (2002) Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. Am J Clin Oncol 25: 354-357
19. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 145-146
20. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115
21. Louvet C, Coudray AM, Tournigand C, Prevost T, Raymond E, de Gramobt A, Chazard M, Gespach C (2000) Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs 11: 579-582
22. Louvet C, de Gramont A (2003) Colorectal cancer: integrating oxaliplatin. Curr Treat Option Oncol 4: 405-411
23. Makatsoris T, Papadimitrou C, Karina M, Aravantinos G, Economopoulos T, Bamias A, Vassilakopoulou M, Xiros N, Kalofonos HP, Fountzilas G (2003) A phase II study of capecitabine and oxaliplatin as first line treatment for advanced colorectal carcinoma (CRC). A Hellenic Cooperative Oncology Group (He COG) study. Proc Am Soc Clin Oncol 22: 360 (abstr. 1447)
24. Mayer RJ (2001) Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol 19: 4093-4096
25. Meta-Analysis Group in Cancer (1998a) Efficacy of intravenous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
26. Meta-Analysis Group in Cancer (1998b) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541
27. Raymond E, Buguet-Fagot C, Djelloul S, Mester J, Cvitkovic E, allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor A337 in human colon, breast and ovarian cancer. Anticancer Drugs 8: 876-885
28. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
29. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
30. Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2002) A phase II trial of oxaliplatin and capecitabine in patents with advanced colorectal cancer. Proc Am Soc Clin Oncol 21: 143 (abstr. 568)
31. Simpson D, Dunn C, Curren M, Goa KL (2003) Oxaliplatin. A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 63: 2127-2156
32. Tabernero J, Butts CA, Cassidy J, Conroy T, de Braud F, Díaz-Rubio E, Figer A, Schoeffski P, Grossmann J, Sobrero A, Twelves C, Van Cutsem E (2003) Capecitabine and oxaliplatin in combination (Xelox), as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international phase II trial. Proc Am Soc Clin Oncol 21: 133 (abstr. 531)
33. World Health Organization 1979 WHO Handbook for Reporting Results of Cancer Treatment WHO offset publication no. 48. Geneva, Switzerland: WHO
34. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F (2003) Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14: 1378-1382